PerCP/Cy5.5 anti-human CD326 (EpCAM)

Catalog # / Size: 2221070 / 100 tests

2221065 / 25 tests

Clone:

Isotype: Mouse IgG2b, κ

DU.4475 breast carcinoma Immunogen:

Reactivity: Human

Preparation: The antibody was purified by affinity

chromatography, and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated


antibody.

Formulation: Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide and

0.2% (w/v) BSA (origin USA).

Concentration: Lot-specific



Human colon carcinoma cell line HT29 stained with 9C4 PerCP/Cy5.5

Applications:

Applications: Flow Cytometry

Recommended

Usage:

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for

each application.

* PerCP/Cy5.5 has a maximum absorption of 482 nm and a maximum emission of

690 nm.

Application Notes: Additional reported applications (for the revelant formats) include:

immunofluorescence and immunohistochemistry3.

Application References: 1. Lammers R, et al. 2002. Exp. Hematol. 30:537.

2. Schultz LD, et al. 2010. P. Natl. Acad. Sci. USA 107:13022. PubMed

3. Human Protein Atlas http://www.proteinatlas.org/ENSG00000119888/antibody

4. Cai X. et al. 2014. PLoS One. 9:108942. PubMed

5. Cheah MT, et al. 2015. PNAS. 112:4725. PubMed

Description:

CD326 is also known as Ep-CAM, tumor associated calcium signal transducer 1, epithelial cell surface antigen, epithelial glycoprotein 2, EGP2, adenocarcinoma associated antigen, and TROP1. CD326 is a type I transmembrane protein containing six disulfide bridges and one THYRO domain. This cell surface glycosylated 40 kD protein is highly expressed in bone marrow, colon, lung, and most normal epithelial cells and is expressed on carcinomas of gastrointestinal origin. Recently, it has been reported that CD326 expression occurs during the early steps of erythrogenesis. CD326 functions as a homotypic calciumindependent cell adhesion molecule and is believed to be involved in carcinogenesis by its ability to induce genes involved in cellular metabolism and proliferation. CD326 antigen is an immunotherapeutic target for the treatment of human carcinomas.

Antigen References:

Strnad J, et al. 1989. Cancer Res. 49:314.
Munz M, et al. 2004. Oncogene 23:5748.

3. Rao CG, et al. 2005. Int. J. Oncol. 27:49.